Navigation Links
Neurochem Annual and Special Meeting of shareholders
Date:4/11/2008

.

To Contact Neurochem

For additional information on Neurochem and its programs, please call the North American toll-free number 1-877-680-4500 or visit the Company's Web site at http://www.neurochem.com.

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Neurochem Inc.'s control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical and/or nutraceutical industry, changes in the regulatory environment in the jurisdictions in which the Neurochem group does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, that actual results may vary once the final and quality-controlled verification of data and analyses has been completed, as well as other risks disclosed in public filings of Neurochem Inc. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These statements speak only as of the date made and Neurochem Inc. is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation. Please see the Annual Information Form of Neurochem Inc. for further risk factors that might affect the Neurochem group and its business.

For further information, please contact:
Lise Hebert, PhD Vice President, Corporate Communications Tel: 450-680
'/>"/>

SOURCE NEUROCHEM INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis
2. Neurochem announces departure of two members of management team
3. Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives
4. Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast live
5. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
6. Neurochem to present at JPMorgan Healthcare Conference
7. Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
8. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
9. Neurochem announces departure of Dr. Philippe Calais, President, Global Business
10. Neurochem reports results for third quarter of fiscal 2007
11. With annual deaths from malaria on the rise: Scientists ask where is all the money going?

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)... Older males saw their odds drop by 63 percent wi..., MONDAY, Nov. 23 (HealthDay News) -- Moderate-to... or tennis may help reduce stroke risk in older me...tudy included almost 3,300 men and women, average ...ine years. During that time, there were 238 stroke...
(Date:11/23/2009)... Dr. Bernadine Healy, first woman to head the age...DAY, Nov. 23 (HealthDay News) -- The fallout from ...n delay the start of routine mammogram testing for...e U.S. National Institutes of Health advising wome...powerfully ignore them, because unequivocally this...
(Date:11/23/2009)... ,, CENTERCITY,Minn.,Nov.23/PRNewswire/--Haz...treatmentcenter,todayannouncedtheleadershipteamfor...bedfacilityinNaplesisscheduledtoopeninlateMarch201...sforadults,includingafullarrayoffamilyandoutpatien...ecutivedirectorofHazelden,sfacilityinNaples,withBr...
(Date:11/23/2009)... ,, $4Million Alliance ProgramSupportsFut...nshipGuideAvailableat www.Allia n ceS ...ire-USNewswire/--"Mr.President,youcancountusin.Wit...lianceisproudtobeapartofEducatetoInnovate,"saidAdo...ceforHispanicHealth,afterattendingaWhiteHousemeeti...
(Date:11/23/2009)... ,, TUCSON,Ariz.,Nov.23/PRNewswire/--Cortiva...apyWorkshoponSunday,Dec.6from1-3p.m.attheschool,s6...ortunityforparticipantstolearnandpracticebasicmass...dCortivaInstituteTucsonisgrowingrightalongwithit,"...n. ,, Infact,theU.S.DepartmentofLabor,s2009-201...
Breaking Medicine News(10 mins):Health News:Vigorous Exercise Cuts Stroke Risk for Men, Not Women 2Health News:Women Should Ignore New Mammogram Guideline, Ex-NIH Chief Says 2Health News:Women Should Ignore New Mammogram Guideline, Ex-NIH Chief Says 3Health News:Hazelden Names Leadership Team for New Recovery Center in Naples, Florida 2Health News:Alliance Joins President Obama at White House in Commitment to Science, Technology, Engineering, and Math (STEM) Education 2Health News:Cortiva Institute To Host Workshop, Hands-On Opportunity for Prospective Students 2
... Illinois will host a first-of-its-,kind celebrati...s and,friends. The BIG Night Out - Indulgence for...om 6:30 p.m. to 10:00 p.m. in the Great Hall of Ch...olates,scrumptious hors d,ouevres and martinis mad...
... /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals,...t signed amended,agreements with Smith & Nephew wo...icoat(TM) dressings with SILCRYST(TM) nanocrystall...o grant,NUCRYST exclusive manufacturing rights, pl...
... Oct. 1 UTC Power, a,United Technologies Corp. (N...ed Dome- Tech Group, a national energy consulting ...y. Financial terms were not disclosed. Dome-Tech ...d carbon footprint reduction, smart energy,procure...
...Capabilities that Help Patients Achieve Optimum He....,(Nasdaq: VTIV ) today announced that it has lau...Outcomes, with a focus on helping pharmaceutical,c... wins -,the healthcare providers, the pharmaceutic...
... Increasing New Jersey Life Sciences Jobs With ... PARSIPPANY, N.J., Oct. 1 Daiichi Sankyo, Inc. ha...s and rapidly increasing its,staffing since 2002 t...cal companies experiencing steady and sustained,gr...
...ty Awareness Month, WHITE PLAINS, N.Y., Oct. 1 M...h the March of Dimes to help give,every baby their...ternity,a national sponsor of the March of Dimes P...to save babies from,premature birth. "We are plea...
Other Medicine News:Health News:Y-ME Illinois Hosts the First-Ever 'BIG Night Out' - Indulgence for a Cause 2Health News:NUCRYST and Smith & Nephew Revise Agreements 2Health News:NUCRYST and Smith & Nephew Revise Agreements 3Health News:NUCRYST and Smith & Nephew Revise Agreements 4Health News:NUCRYST and Smith & Nephew Revise Agreements 5Health News:NUCRYST and Smith & Nephew Revise Agreements 6Health News:NUCRYST and Smith & Nephew Revise Agreements 7Health News:UTC Power Acquires Dome-Tech Group 2Health News:inVentiv Health Launches Fourth Business Segment: inVentiv Patient Outcomes 2Health News:inVentiv Health Launches Fourth Business Segment: inVentiv Patient Outcomes 3Health News:Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firms Downsize 2Health News:Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firms Downsize 3Health News:Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firms Downsize 4Health News:Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firms Downsize 5Health News:Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firms Downsize 6Health News:Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firms Downsize 7Health News:Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firms Downsize 8Health News:Motherhood(R) Maternity Joins March of Dimes to Give Babies a Healthy Start in Life 2
(Date:11/23/2009)...swire-FirstCall/--CordBloodAmerica,Inc.(OTCBulleti...tioncompany( http://www.cordblood-america.com )foc...iologicalinsurancepolicy,tofamiliesnationwideandin...nterviewwithCEOandco-founderMatthewSchisslerisnowa...p.tv/file/2875811 . ,, Intheinterview,Mr.Schiss...
(Date:11/23/2009).../PRNewswire-FirstCall/--Pharmasset,Inc.(Nasdaq: VR...itspartnerRoche(SWX:ROG.VX;RO.S,OTCQX:RHHBY),willc...eongoingphase2btrialofRG7128,afirst-in-classnucleo...nichepatitisCvirus(HCV)infection.Thedecisionwasrea...ringCommittee(DMC)ofallavailablesafetydatafromthef...
(Date:11/23/2009)...PRNewswire-FirstCall/--RaptorPharmaceuticalCorp.("...edresultsfromaPhase2bclinicaltrialofitsproprietary...)inpatientswithnephropathiccystinosis("cystinosis"...nDiego("UCSD")GeneralClinicalResearchCenter,evalua...dynamicsofasingledoseofDRCysteamineinninecystinosi...
Breaking Medicine Technology:Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 2Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 3Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 4Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 2Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 3Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 4Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 5FDA Panel Weighs Approving HPV Vaccine for Males 56544 1FDA Panel Weighs Approving HPV Vaccine for Males 56544 2FDA Panel Weighs Approving HPV Vaccine for Males 56544 3CONCERTA 28R 29 28methylphenidate HCI 29 LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 56540 1CONCERTA 28R 29 28methylphenidate HCI 29 LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 56540 2CONCERTA 28R 29 28methylphenidate HCI 29 LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 56540 3CONCERTA 28R 29 28methylphenidate HCI 29 LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 56540 4CONCERTA 28R 29 28methylphenidate HCI 29 LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 56540 5Cash For Crows Feet Program Offers Effective and Affordable Laser Skin Treatments 56536 1Cash For Crows Feet Program Offers Effective and Affordable Laser Skin Treatments 56536 2
... Efficacy of Treating Patients with ...nd YONGIN-SI, South Korea, July 22 ,Jennerex, Inc....South,Korean partner Green Cross Corp., announced ...trial of its first-in-class lead product JX-594,de... resulted in clear,anti-cancer efficacy in patient...
...rapy and pegylated enzyme produces significantl... - - Pegylated enzyme well tolera...Inc. (Nasdaq: HALO ), a biopharmaceutical company... the extracellular matrix, today,announced the pre... data,for its pegylated-rHuPH20 enzyme (PEGPH20) a...
Other Medicine Technology:Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 2Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 4Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 2Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 3Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 4Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 5
HSV 2 IgG II ELISA
Avci Foreign Body Forceps 20 gauge / 0.9 mm
Microforceps: Horizontal Subretinal
Microforceps: Claes ILM Forceps
Medicine Products: